Opexa Therapeutics (OPXA) Stock Climbs On CEO Presentation

1

Opexa Conference Main Points FinancialsOpexa Therapeutics Inc (NASDAQ: OPXA)

Opexa Therapeutics stock is climbing today as a result of a presentation at the 2015 Marcum Microcap Conference that just wrapped up recently. In the presentation, OPXA CEO, Neil K. Warma announced financial information as well as information on the company’s pipeline and goals moving forward; and I have to say, I’m pretty impressed. So below, we’ll discuss some of the key points from the presentation and talk about what we’re expecting to see moving forward. So, lets get right to it.

Main Points From The Opexa Therapeutics Presentation

There were 4 main points that were discussed in the presentation….

  • Finances – In the presentation investors learned that Opexa Therapeutics has absolutely no debt! The company currently has cash and cash equivalents in the amount of about $9.6 million. Rights offering net proceeds came in around $12 million. Outstanding shares are valued at about $53.4 million.
  • Pipeline – When it comest o the company’s pipeline, there was a big announcement made today. First off, Tcelna, the company’s prime candidate not only has very limited competition, but is currently in Phase 2b for secondary progressive multiple sclerosis (SPMS) and has an overall market potential around $7 billion. The company also announced an addition to their pipeline known as OPX-212; which they hope will prove to be an effective treatment for neuromyelitis optica, an ailment with no approved therapies at the moment. That makes OPX-212 the first treatment in the Opexa Therapeutics pipeline on the orphan indication side of the fence.
  • Technology – Warma also discussed a personalized T-cell immunotherapy platform for autoimmune disease. The therapy is custom tailored to patients; hopefully making it an effective way to treat the disease. They also talked about a company owned and scalable eGMP manufacturing facility, and the fact that OPXA now holds 98 domestic patents.
  • Validation – Finally, Warma discussed validation the company has received validation with regard to Tcelna for SPMS through a potential partnership with Merck Serono and the fact that the company has received FDA Fast Track Designation for the approval of the treatment.

All in all, everything we heard seemed to be overwhelmingly positive news.

What We Can Expect To See Moving Forward

I think the presentation today was a major step for OPXA. As a micro-cap in the biotech space with no approved treatments, I find the fact that the company, has maintained a debt-free position to be incredible. Also, the company has a strong pipeline, incredible technology, and they’ve received validation with regard to their prime candidate. With strong management and clear goals, I think this one’s headed to the top in the long run!

What Do You Think?

Where do you think OPXA is headed and why? Let us know in the comments below!

1 COMMENT

  1. Great synopsis on the day Joshua! I believe with the presure of delising upon them, OPXA has no choice but to unleash the hounds and do everything they can to get the PPS up and above the $1, which isn’t going to be a problem. I see the $5 mark absolutely obtainable by end of year.

LEAVE A REPLY

Please enter your comment!
Please enter your name here